Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 1
2010 2
2012 1
2013 1
2014 1
2015 2
2016 1
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.
Laurichesse H, Zimmermann U, Galtier F, Launay O, Duval X, Richard P, Sadorge C, Soubeyrand B. Laurichesse H, et al. Hum Vaccin Immunother. 2012 Dec 1;8(12):1875-81. doi: 10.4161/hv.22083. Epub 2012 Oct 2. Hum Vaccin Immunother. 2012. PMID: 23032160 Free PMC article. Clinical Trial.
In adults with a tetanus-prone injury, combined vaccines such as Tdap-IPV (REPEVAX) can boost immunity against several diseases simultaneously. ...
In adults with a tetanus-prone injury, combined vaccines such as Tdap-IPV (REPEVAX) can boost immunity against several diseases simul …
Humoral immunity of dTap-IPV vaccine (REPEVAX) administered one month after dT-IPV vaccine (REVAXIS) in adults with unknown vaccination history.
Larnaudie S, Guiso N, Baptiste C, Desaint C, Desforges L, Lebon P, Soubeyrand B, Launay O. Larnaudie S, et al. Hum Vaccin. 2010 Oct;6(10):829-34. doi: 10.4161/hv.6.10.12582. Epub 2010 Oct 1. Hum Vaccin. 2010. PMID: 20864810
Antibodies against diphtheria, tetanus, poliomyelitis types 1, 2 and 3, and pertussis toxin (PT) were measured one month after the administration of REPEVAX (Visit 3). A total of 136 subjects were included in the study, but blood samples were available for only 73 subjects …
Antibodies against diphtheria, tetanus, poliomyelitis types 1, 2 and 3, and pertussis toxin (PT) were measured one month after the administr …
Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged 60 years: an open-label, randomised trial.
Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Zimmermann U, et al. Vaccine. 2013 Mar 1;31(11):1496-502. doi: 10.1016/j.vaccine.2012.12.081. Epub 2013 Jan 10. Vaccine. 2013. PMID: 23313654 Clinical Trial.
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R, Kuriyakose S, Mesaros N, Han HH, Tomlinson R, Faust SN, Snape MD, Pollard AJ, Finn A. Marlow R, et al. Vaccine. 2018 Apr 19;36(17):2300-2306. doi: 10.1016/j.vaccine.2018.03.021. Epub 2018 Mar 22. Vaccine. 2018. PMID: 29576304 Free article. Clinical Trial.
AIM: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPV(B)) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3-4 year old children as compared to dTap-IPV(R) (Repevax, Sanofi Pasteur) …
AIM: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPV( …
An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.
Kosalaraksa P, Mehlsen J, Vesikari T, Forstén A, Helm K, Van Damme P, Joura EA, Ciprero K, Maansson R, Luxembourg A, Sobanjo-ter Meulen A. Kosalaraksa P, et al. Pediatr Infect Dis J. 2015 Jun;34(6):627-34. doi: 10.1097/INF.0000000000000694. Pediatr Infect Dis J. 2015. PMID: 25831420 Clinical Trial.
We evaluated the immunogenicity and safety of the 9vHPV vaccine administered concomitantly with REPEVAX (diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine). ...CONCLUSION: Overall, concomitant administration of 9vHPV vaccine and REPEVAX
We evaluated the immunogenicity and safety of the 9vHPV vaccine administered concomitantly with REPEVAX (diphtheria, tetanus, acellul …
An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, Ryan D, Vuocolo S, Haupt RM, Guris D. Vesikari T, et al. Pediatr Infect Dis J. 2010 Apr;29(4):314-8. doi: 10.1097/INF.0b013e3181c177fb. Pediatr Infect Dis J. 2010. PMID: 19952980 Clinical Trial.
All subjects received a 0.5 mL dose of GARDASIL at day 1, month 2, and month 6, and a 0.5 mL dose of REPEVAX either on day 1 (opposite limb from GARDASIL) or at month 1. ...CONCLUSION: Overall, concomitant administration of GARDASIL and REPEVAX was generally well-to …
All subjects received a 0.5 mL dose of GARDASIL at day 1, month 2, and month 6, and a 0.5 mL dose of REPEVAX either on day 1 (opposit …
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents.
Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Perez JL. Vesikari T, et al. J Pediatric Infect Dis Soc. 2016 Jun;5(2):180-7. doi: 10.1093/jpids/piv064. Epub 2016 Jan 23. J Pediatric Infect Dis Soc. 2016. PMID: 26803328 Free PMC article. Clinical Trial.
BACKGROUND: Bivalent rLP2086, a Neisseria meningitidis serogroup B (MnB) vaccine (Trumenba [Pfizer, Inc]) recently approved in the United States to prevent invasive MnB disease in individuals aged 10-25 years, contains recombinant subfamily A and B factor H binding proteins (fHBP …
BACKGROUND: Bivalent rLP2086, a Neisseria meningitidis serogroup B (MnB) vaccine (Trumenba [Pfizer, Inc]) recently approved in the United St …
Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine.
Kitchin N, Southern J, Morris R, Borrow R, Fiquet A, Boisnard F, Thomas S, Miller E. Kitchin N, et al. Vaccine. 2009 Aug 13;27(37):5096-102. doi: 10.1016/j.vaccine.2009.06.049. Epub 2009 Jun 30. Vaccine. 2009. PMID: 19573637 Clinical Trial.
Administration of an acellular pertussis-containing quadrivalent pre-school booster (Td(5)ap-IPV; Repevax), with or without measles, mumps and rubella (M-M-RII) vaccine, induced robust antibody responses indicative of protection, regardless of the vaccine used for the prim …
Administration of an acellular pertussis-containing quadrivalent pre-school booster (Td(5)ap-IPV; Repevax), with or without measles, …
Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T, Voysey M, Yu LM, McCarthy N, Baudin M, Richard P, Fiquet A, Kitchin N, Pollard AJ. John T, et al. Vaccine. 2015 Aug 26;33(36):4579-85. doi: 10.1016/j.vaccine.2015.06.105. Epub 2015 Jul 10. Vaccine. 2015. PMID: 26165918 Free article. Clinical Trial.
Children had previously been randomised to receive one of three combination vaccines: either a combined adsorbed tetanus, low-dose diphtheria, 5-component acellular pertussis and inactivated polio vaccine (IPV) (Tdap-IPV, Repevax(); Sanofi Pasteur MSD); a combined adsorbed …
Children had previously been randomised to receive one of three combination vaccines: either a combined adsorbed tetanus, low-dose diphtheri …
11 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page